• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, September 11, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Trends in reoperation after initial lumpectomy for breast cancer

Bioengineer by Bioengineer
June 5, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Monica Morrow, M.D., of Memorial Sloan Kettering Cancer Center, New York, and coauthors investigated the impact of a 2014 consensus statement endorsing a minimal negative margin for invasive breast cancer on postlumpectomy surgery and final surgical treatment.

There had been wide variation in attitudes about what was considered an appropriate negative margin width for lumpectomy. Reoperation after initial lumpectomy has major treatment implications for patients.

The population-based study, which included 3,729 women undergoing initial lumpectomy between 2013 and 2015, describes the approach by surgeons to surgical margins for invasive breast cancer and changes in postlumpectomy surgery rates and final surgical treatment following the 2014 consensus statement that endorsed a margin of "no ink on tumor."

The authors report reexcision and conversion to mastectomy declined among patients with negative margins and final rates of breast-conserving surgery increased from 52 percent to 65 percent with a decrease in both unilateral and bilateral mastectomy.

The study, which notes some limitations, concludes: "Our findings provide support for an argument that evidence-based, multidisciplinary guidelines that address issues of clinical controversy can be an effective relatively low-cost approach to accelerating practice change and reducing overtreatment in cancer care."

###

For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/jamaoncol.2017.0774)

Editor's Note: The article contains funding support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Related audio material: An author audio interview is available for preview on the For The Media website. The podcast will be live when the embargo lifts on the JAMA Oncology website.

To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2017.0774

Media Contact

Emily O'Donnell
[email protected]
@JAMA_current

http://www.jamamedia.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Boosting Immune Responses via Proximity Labeling

September 10, 2025

Impact of Teamwork and Competition on STEM Engagement

September 10, 2025

Transforming Postgraduate Nursing: Journal Club Insights

September 10, 2025

Unraveling Gene Expression Mechanisms in Glioblastoma

September 10, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    62 shares
    Share 25 Tweet 16
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Boosting Immune Responses via Proximity Labeling

Impact of Teamwork and Competition on STEM Engagement

Transforming Postgraduate Nursing: Journal Club Insights

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.